The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $57.08 in the prior trading day, Legend Biotech Corp ADR (NASDAQ: LEGN) closed at $54.68, down -4.20%. In other words, the price has decreased by -$4.20 from its previous closing price. On the day, 0.99 million shares were traded. LEGN stock price reached its highest trading level at $58.0 during the session, while it also had its lowest trading level at $54.64.
Ratios:
Our goal is to gain a better understanding of LEGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.78 and its Current Ratio is at 4.84. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.29.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on June 17, 2024, initiated with a Buy rating and assigned the stock a target price of $88.
On May 24, 2024, H.C. Wainwright reiterated its Buy rating and also upped its target price recommendation from $86 to $73.
On May 23, 2024, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $60.Deutsche Bank initiated its Buy rating on May 23, 2024, with a $60 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 10015791104 and an Enterprise Value of 19957854208. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.96 while its Price-to-Book (P/B) ratio in mrq is 8.64. Its current Enterprise Value per Revenue stands at 43.768 whereas that against EBITDA is -55.066.
Stock Price History:
Over the past 52 weeks, LEGN has reached a high of $72.38, while it has fallen to a 52-week low of $38.60. The 50-Day Moving Average of the stock is 9.49%, while the 200-Day Moving Average is calculated to be -1.10%.
Shares Statistics:
The stock has traded on average 1.18M shares per day over the past 3-months and 846260 shares per day over the last 10 days, according to various share statistics. A total of 181.91M shares are outstanding, with a floating share count of 181.66M. Insiders hold about 0.83% of the company’s shares, while institutions hold 47.05% stake in the company. Shares short for LEGN as of 1722384000 were 10075900 with a Short Ratio of 8.53, compared to 1719532800 on 11164706. Therefore, it implies a Short% of Shares Outstanding of 10075900 and a Short% of Float of 10.520000999999999.
Earnings Estimates
The market rating for Legend Biotech Corp ADR (LEGN) is a result of the insights provided by 7.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.14 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$0.53 and -$1.71 for the fiscal current year, implying an average EPS of -$1.17. EPS for the following year is -$0.7, with 10.0 analysts recommending between $0.4 and -$1.63.
Revenue Estimates
12 analysts predict $134.69M in revenue for the current quarter. It ranges from a high estimate of $145.15M to a low estimate of $113.3M. As of the current estimate, Legend Biotech Corp ADR’s year-ago sales were $96.01MFor the next quarter, 12 analysts are estimating revenue of $175.87M. There is a high estimate of $215.44M for the next quarter, whereas the lowest estimate is $154.83M.
A total of 20 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $639M, while the lowest revenue estimate was $463.86M, resulting in an average revenue estimate of $569.97M. In the same quarter a year ago, actual revenue was $285.14MBased on 21 analysts’ estimates, the company’s revenue will be $1.05B in the next fiscal year. The high estimate is $1.31B and the low estimate is $841.4M.
